Which has better earnings and valuation, CRMD or ADAG?

CorMedix has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 2.11 $163.05M $2.13 3.94 Adagene $7.67M 26.26 -$17.61M N/A N/A

Is CRMD or ADAG more profitable?

CorMedix has a net margin of 45.25% compared to Adagene's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Adagene's return on equity. Company Net Margins Return on Equity Return on Assets CorMedix 45.25% 45.57% 24.76% Adagene N/A N/A N/A

Does the media prefer CRMD or ADAG?

In the previous week, CorMedix had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Adagene. Adagene's average media sentiment score of 0.36 beat CorMedix's score of 0.34 indicating that Adagene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ADAG or OCS?

Adagene has higher revenue and earnings than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 26.26 -$17.61M N/A N/A Oculis $1.45M 462.24 -$119.44M -$2.13 N/A

Is ADAG or OCS more profitable?

Adagene has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Adagene's return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Oculis -8,460.67% -56.78% -45.62%

Does the media favor ADAG or OCS?

In the previous week, Oculis had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Adagene. Adagene's average media sentiment score of 0.36 beat Oculis' score of 0.00 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ALLO or ADAG?

Adagene has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 35,377.88 -$190.89M -$0.77 N/A Adagene $7.67M 26.26 -$17.61M N/A N/A

Is ALLO or ADAG more profitable?

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Adagene N/A N/A N/A

Which has stronger earnings & valuation, ADAG or RLMD?

Adagene has higher revenue and earnings than Relmada Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 26.26 -$17.61M N/A N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is ADAG or RLMD more profitable?

Adagene's return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Relmada Therapeutics N/A -71.22% -64.46%

Does the media favor ADAG or RLMD?

In the previous week, Relmada Therapeutics had 16 more articles in the media than Adagene. MarketBeat recorded 17 mentions for Relmada Therapeutics and 1 mentions for Adagene. Relmada Therapeutics' average media sentiment score of 1.05 beat Adagene's score of 0.36 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AURA or ADAG?

Adagene has higher revenue and earnings than Aura Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Adagene $7.67M 26.26 -$17.61M N/A N/A

Is AURA or ADAG more profitable?

Adagene's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Adagene N/A N/A N/A

Adagene (ADAG) Competitors

$4.25 +0.27 (+6.78%)

Closing price 04:00 PM Eastern

Extended Trading

$4.25 0.00 (0.00%)

As of 07:29 PM Eastern

Compare

ADAG vs. CRMD, OCS, ALLO, RLMD, and AURA

Should you buy Adagene stock or one of its competitors? MarketBeat compares Adagene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adagene include CorMedix (CRMD), Oculis (OCS), Allogene Therapeutics (ALLO), Relmada Therapeutics (RLMD), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.

How does Adagene compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 78.78%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 88.24%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CorMedix had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Adagene. Adagene's average media sentiment score of 0.36 beat CorMedix's score of 0.34 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Adagene has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

CorMedix has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.11	$163.05M	$2.13	3.94
Adagene	$7.67M	26.26	-$17.61M	N/A	N/A

CorMedix has a net margin of 45.25% compared to Adagene's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Adagene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Adagene	N/A	N/A	N/A

Summary

CorMedix beats Adagene on 9 of the 15 factors compared between the two stocks.

How does Adagene compare to Oculis?

Adagene (NASDAQ:ADAG) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Oculis had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Adagene. Adagene's average media sentiment score of 0.36 beat Oculis' score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.5% of Adagene shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adagene presently has a consensus price target of $8.00, indicating a potential upside of 88.24%. Oculis has a consensus price target of $38.33, indicating a potential upside of 231.60%. Given Oculis' higher possible upside, analysts clearly believe Oculis is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Adagene has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Adagene's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Oculis	-8,460.67%	-56.78%	-45.62%

Adagene has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Oculis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Adagene has higher revenue and earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	26.26	-$17.61M	N/A	N/A
Oculis	$1.45M	462.24	-$119.44M	-$2.13	N/A

Summary

Adagene beats Oculis on 10 of the 15 factors compared between the two stocks.

How does Adagene compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Adagene had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Allogene Therapeutics. Adagene's average media sentiment score of 0.36 beat Allogene Therapeutics' score of -1.74 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Very Negative
Adagene	Neutral

Adagene has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	35,377.88	-$190.89M	-$0.77	N/A
Adagene	$7.67M	26.26	-$17.61M	N/A	N/A

Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Allogene Therapeutics presently has a consensus target price of $8.52, suggesting a potential upside of 315.72%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 88.24%. Given Allogene Therapeutics' higher possible upside, equities analysts plainly believe Allogene Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Adagene	N/A	N/A	N/A

Summary

Adagene beats Allogene Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Adagene compare to Relmada Therapeutics?

Adagene (NASDAQ:ADAG) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Adagene's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Relmada Therapeutics	N/A	-71.22%	-64.46%

Adagene presently has a consensus price target of $8.00, indicating a potential upside of 88.24%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 84.19%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Relmada Therapeutics had 16 more articles in the media than Adagene. MarketBeat recorded 17 mentions for Relmada Therapeutics and 1 mentions for Adagene. Relmada Therapeutics' average media sentiment score of 1.05 beat Adagene's score of 0.36 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has higher revenue and earnings than Relmada Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	26.26	-$17.61M	N/A	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Adagene has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

9.5% of Adagene shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Adagene beats Relmada Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Adagene compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Adagene had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.94 beat Adagene's score of 0.36 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aura Biosciences	Positive
Adagene	Neutral

Aura Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aura Biosciences presently has a consensus target price of $20.50, indicating a potential upside of 191.19%. Adagene has a consensus target price of $8.00, indicating a potential upside of 88.24%. Given Aura Biosciences' higher probable upside, equities analysts clearly believe Aura Biosciences is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Adagene	N/A	N/A	N/A

Adagene has higher revenue and earnings than Aura Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Adagene	$7.67M	26.26	-$17.61M	N/A	N/A

Summary

Adagene beats Aura Biosciences on 9 of the 12 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$188.60M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	N/A	20.50	25.39	23.96
Price / Sales	26.26	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	5.67	8.26	10.76	6.41
Net Income	-$17.61M	$23.91M	$3.56B	$337.14M
7 Day Performance	20.40%	3.05%	1.37%	-0.48%
1 Month Performance	13.33%	2.40%	0.81%	0.49%
1 Year Performance	118.51%	56.35%	30.53%	28.16%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	2.508 of 5 stars	$4.25 +6.8%	$8.00 +88.2%	+108.9%	$188.60M	$7.67M	N/A	260	Gap Down High Trading Volume
CRMD CorMedix	3.4477 of 5 stars	$8.66 +0.8%	$15.00 +73.2%	-48.1%	$673.90M	$311.71M	4.07	30	News Coverage
OCS Oculis	2.8305 of 5 stars	$11.45 -1.4%	$38.33 +234.8%	-40.4%	$673.20M	$1.45M	N/A	2
ALLO Allogene Therapeutics	2.3484 of 5 stars	$1.90 -2.1%	$8.52 +348.5%	+69.7%	$669.60M	$20K	N/A	310
RLMD Relmada Therapeutics	2.279 of 5 stars	$6.55 +2.8%	$12.00 +83.2%	+1,009.8%	$668.15M	N/A	N/A	10	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. CRMD, OCS, ALLO, RLMD, and AURA

How does Adagene compare to CorMedix?

Summary

How does Adagene compare to Oculis?

Summary

How does Adagene compare to Allogene Therapeutics?

Summary

How does Adagene compare to Relmada Therapeutics?

Summary

How does Adagene compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. CRMD, OCS, ALLO, RLMD, and AURA

How does Adagene compare to CorMedix?

Do analysts prefer CRMD or ADAG?

Do insiders and institutionals have more ownership in CRMD or ADAG?

Does the media prefer CRMD or ADAG?

Which has more volatility & risk, CRMD or ADAG?

Which has better earnings and valuation, CRMD or ADAG?

Is CRMD or ADAG more profitable?

Summary

How does Adagene compare to Oculis?

Does the media favor ADAG or OCS?

Do insiders and institutionals believe in ADAG or OCS?

Do analysts rate ADAG or OCS?

Is ADAG or OCS more profitable?

Which has more risk & volatility, ADAG or OCS?

Which has preferable valuation and earnings, ADAG or OCS?

Summary

How does Adagene compare to Allogene Therapeutics?

Does the media refer more to ALLO or ADAG?

Which has stronger earnings and valuation, ALLO or ADAG?

Which has more risk and volatility, ALLO or ADAG?

Do institutionals and insiders hold more shares of ALLO or ADAG?

Do analysts rate ALLO or ADAG?

Is ALLO or ADAG more profitable?

Summary

How does Adagene compare to Relmada Therapeutics?

Is ADAG or RLMD more profitable?

Do analysts prefer ADAG or RLMD?

Does the media favor ADAG or RLMD?

Which has stronger earnings & valuation, ADAG or RLMD?

Which has more risk & volatility, ADAG or RLMD?

Do insiders and institutionals hold more shares of ADAG or RLMD?

Summary

How does Adagene compare to Aura Biosciences?

Does the media refer more to AURA or ADAG?

Which has more risk and volatility, AURA or ADAG?

Do institutionals & insiders believe in AURA or ADAG?

Do analysts rate AURA or ADAG?

Is AURA or ADAG more profitable?

Which has higher earnings & valuation, AURA or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools